Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The company’s shares closed last Friday at $324.86.

In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $317.58, changing hands for $317.82/share. When a stock reaches the target an ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other undervalued stocks. On March 5th, BBC reported that the US stock market had fallen after the ...

Amgen’s dividend payout ratio is currently 126.09%. Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to ...

Shares of Apple and Amgen are seeing declines Wednesday afternoon, sending the Dow Jones Industrial Average into negative territory. Supported by world-class markets data from Dow Jones and ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen (NASDAQ:AMGN) shares snapped six straight sessions of gains, as the stock ended 3% lower at $306.2 on Wednesday. The biotechnology company gained 7.8% in the preceding six sessions. The ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best retirement stocks to buy according to hedge funds. After much suspense, the US Federal ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best performing Dow ...

EXCLUSIVE: Revelyst Inc., a collective of brands that design and manufacture performance gear, has signed a multiyear partnership with Sierra Pictures, the production, advisory and financing ...